Technology area: Biotechnology & Pharmaceuticals
50 pending office actions • 25 art units • 45 examiners • 0 of 50 (0%) have an AI response strategy ready • 15 patents granted in the last 365 days
Flagship Pioneering Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 distinct examiners and 2 distinct art units.
WHITEMAN, BRIAN A is the busiest examiner, with 1 pending matter. The small docket supports direct review of both applications and does not show a recurring examiner or technical-unit concentration.
Based on the USPTO statutory response window for each pending office action. 22 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 22 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (2%) |
| §101 + other | 11 (22%) |
| §103 only | 7 (14%) |
| §112 only | 3 (6%) |
| Double-patenting + other | 9 (18%) |
| Multi-statute (no §101) | 19 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEITH, NANCY J | 2 | 74.7% | +44.0% |
| GILL, RACHEL B | 2 | 65.4% | +28.8% |
| DAUNER, JOSEPH G | 2 | 57.0% | +35.3% |
| ZARA, JANE J | 2 | 71.0% | +16.1% |
| GIBBS, TERRA C | 2 | 63.7% | +10.4% |
| KEOGH, MATTHEW R | 1 | 78.5% | +14.4% |
| SKIBINSKY, ANNA | 1 | 39.1% | +29.3% |
| HAUK TEODORO, PRICILA NMN | 1 | 50.0% | +0.0% |
| PAULS, JOHN A | 1 | 49.0% | +27.7% |
| SHIAO, REI TSANG | 1 | 79.9% | -33.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19288411 | MULTI-TIERED TESTING FOR TRACKING DISEASE HETEROGENEITY | SKIBINSKY, ANNA | 50d overdue |
| 17920752 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | GIBBS, TERRA C | 29d overdue |
| 16970216 | COMPOSITIONS AND METHODS FOR MEMBRANE PROTEIN DELIVERY | RIGA, MICHAEL ANGELO | 28d overdue |
| 18945759 | SYSTEMS AND METHODS FOR PATIENT TARGETED THERAPY DEVELOPMENT | PAULS, JOHN A | 23d overdue |
| 17792639 | MOLECULE DESIGN | SANFORD, DIANA PATRICIA | 23d overdue |
| 17795915 | COMPOSITIONS FOR TRANSLATION AND METHODS OF USE THEREOF | PYLA, EVELYN Y | 16d overdue |
| 17925920 | CORONAVIRUS ANTIGEN COMPOSITIONS AND THEIR USES | BUCKMASTER, MARLENE VRENI | 10d overdue |
| 17433639 | CIRCULAR POLYRIBONUCLEOTIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ZAHORIK, AMANDA MARY | 8d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19272711 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | LEITH, NANCY J | 89d overdue |
| 19272775 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | LEITH, NANCY J | 86d overdue |
| 19288411 | MULTI-TIERED TESTING FOR TRACKING DISEASE HETEROGENEITY | SKIBINSKY, ANNA | 50d overdue |
| 17920752 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | GIBBS, TERRA C | 29d overdue |
| 18945759 | SYSTEMS AND METHODS FOR PATIENT TARGETED THERAPY DEVELOPMENT | PAULS, JOHN A | 23d overdue |
| 18444227 | COMPOSITIONS AND METHODS FOR MAKING AND USING AN IMMORTALIZED LIBRARY | DAUNER, JOSEPH G | 2d overdue |
| 18474060 | COMPOSITIONS AND METHODS FOR MAKING AND USING AN IMMORTALIZED LIBRARY | DAUNER, JOSEPH G | 70d |
| 17920769 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | GIBBS, TERRA C | 86d |
| Art Unit | Apps |
|---|---|
| 1635 | 7 |
| 1636 | 5 |
| 1637 | 5 |
| 1671 | 3 |
| 1682 | 3 |
| 1634 | 3 |
| 1691 | 2 |
| 1631 | 2 |
| 1633 | 2 |
| 1656 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19303663 | METHODS AND COMPOSITIONS FOR THE MODIFICATION OF PLANTS | KEOGH, MATTHEW R | 1663 | §103§112 | Non-Final OA | — | Pending | Aug 19, 2025 |
| 19288411 | MULTI-TIERED TESTING FOR TRACKING DISEASE HETEROGENEITY | SKIBINSKY, ANNA | 1635 | §101§103 | Non-Final OA | 50d overdue | Pending | Aug 01, 2025 |
| 19272711 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | LEITH, NANCY J | 1636 | §103Other | Final Rejection | 89d overdue | Pending | Jul 17, 2025 |
| 19272775 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | LEITH, NANCY J | 1636 | §103Other | Final Rejection | 86d overdue | Pending | Jul 17, 2025 |
| 18877551 | ADAS COMPRISING TYPE 1 PILI | HAUK TEODORO, PRICILA NMN | 1645 | §103 | Non-Final OA | — | Pending | Dec 20, 2024 |
| 18945759 | SYSTEMS AND METHODS FOR PATIENT TARGETED THERAPY DEVELOPMENT | PAULS, JOHN A | 3683 | §101§103DP | Final Rejection | 23d overdue | Pending | Nov 13, 2024 |
| 18850640 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | SHIAO, REI TSANG | 1691 | §103§112 | Non-Final OA | — | Pending | Sep 25, 2024 |
| 18718549 | METHODS FOR ENRICHMENT OF CIRCULAR RNA UNDER DENATURING CONDITIONS | LEWIS, PATRICK T | 1691 | §102§112 | Non-Final OA | — | Pending | Jun 11, 2024 |
| 18712809 | IMMUNOGENIC COMPOSITIONS AND THEIR USES | GILL, RACHEL B | 1671 | §101§102§103§112DP | Non-Final OA | — | Pending | May 23, 2024 |
| 18712359 | VARICELLA-ZOSTER VIRUS IMMUNOGEN COMPOSITIONS AND THEIR USES | GILL, RACHEL B | 1671 | §101§102§103§112Other | Non-Final OA | — | Pending | May 22, 2024 |
| 18703246 | MODULATORS OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | FAUST, AMBER KATHLEEN | 1643 | §102§112 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18687661 | METHODS AND COMPOSITIONS FOR INDUCING FETAL HEMOGLOBIN, MODULATING ERYTHROID CELL LINEAGES, AND PERTURBING MEGAKARYOCYTE LINEAGES | BARRON, SEAN C | 1653 | §102§112DP | Final Rejection | — | Pending | Feb 28, 2024 |
| 18444227 | COMPOSITIONS AND METHODS FOR MAKING AND USING AN IMMORTALIZED LIBRARY | DAUNER, JOSEPH G | 1682 | §103§112 | Final Rejection | 2d overdue | Pending | Feb 16, 2024 |
| 18569924 | MODIFICATION OF PLANT MESSENGER PACKS | KAMM, JUDITH MARIE | 1611 | §103§112Other | Non-Final OA | — | Pending | Dec 13, 2023 |
| 18561964 | METHODS OF ENRICHING FOR CIRCULAR POLYRIBONUCLEOTIDES | RAVINDRA, KRISHNA NUGGEHALLI | 1636 | §103§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18554139 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS TO ACCEPTOR CELLS | LEONARD, ARTHUR S | 1631 | §101§102§103DP | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18474060 | COMPOSITIONS AND METHODS FOR MAKING AND USING AN IMMORTALIZED LIBRARY | DAUNER, JOSEPH G | 1682 | §103§112Other | Non-Final OA | 70d | Pending | Sep 25, 2023 |
| 18469344 | SERPINA-MODULATING COMPOSITIONS AND METHODS | PERSONS, JENNA L | 1637 | §103§112DP | Non-Final OA | 49d overdue | Pending | Sep 18, 2023 |
| 18464035 | MULTIPLE-TIERED SCREENING AND SECOND ANALYSIS | LIN, JERRY | 1685 | §101§103§112DP | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18038630 | ADIPOGENIC CELL COMPOSITIONS AND METHODS | KIM, TAEYOON | 1631 | §101§102§112 | Non-Final OA | 13d | Pending | May 24, 2023 |
| 18173049 | INTRA-INDIVIDUAL ANALYSIS FOR PRESENCE OF HEALTH CONDITIONS | TURPIN, ZACHARY MARK | 1682 | §101DP | Final Rejection | — | Pending | Feb 22, 2023 |
| 18010857 | METHODS AND COMPOSITIONS FOR MODULATING CELLS AND CELLULAR MEMBRANES | RAHMAN, MASUDUR | 1633 | §102§103 | Final Rejection | 36d | Pending | Dec 17, 2022 |
| 18061632 | TEMPLATE GUIDE RNA MOLECULES | ZARA, JANE J | 1637 | §102§103§112 | Non-Final OA | — | Pending | Dec 05, 2022 |
| 17928463 | TREM COMPOSITIONS AND METHODS RELATING THERETO | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §102§103§112Other | Non-Final OA | — | Pending | Nov 29, 2022 |
| 17925920 | CORONAVIRUS ANTIGEN COMPOSITIONS AND THEIR USES | BUCKMASTER, MARLENE VRENI | 1672 | §103§112 | Final Rejection | 10d overdue | Pending | Nov 17, 2022 |
| 17925966 | IMMUNOGENIC COMPOSITIONS AND USES THEREOF | HILL, MYRON G | 1671 | §103DP | Final Rejection | — | Pending | Nov 17, 2022 |
| 17920752 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | GIBBS, TERRA C | 1635 | §102§103Other | Final Rejection | 29d overdue | Pending | Oct 21, 2022 |
| 17920769 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | GIBBS, TERRA C | 1635 | §103§112DP | Final Rejection | 86d | Pending | Oct 21, 2022 |
| 17929124 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | LEE, JAE W | 1656 | §103§112 | Final Rejection | 6d | Pending | Sep 01, 2022 |
| 17823726 | HOST DEFENSE SUPPRESSING METHODS AND COMPOSITIONS FOR MODULATING A GENOME | KONOPKA, CATHERINE ANNE | 1635 | §112Other | Final Rejection | — | Pending | Aug 31, 2022 |
| 17759838 | Conformal Inference for Optimization | THOMPSON, MILANA KAYE | 1687 | §102§103§112 | Non-Final OA | — | Pending | Jul 29, 2022 |
| 17795915 | COMPOSITIONS FOR TRANSLATION AND METHODS OF USE THEREOF | PYLA, EVELYN Y | 1633 | §101§102§103 | Final Rejection | 16d overdue | Pending | Jul 28, 2022 |
| 17795939 | COMPOSITIONS COMPRISING LINEAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF | JONES-FOSTER, ERICA NICOLE | 1656 | §103§112 | Non-Final OA | — | Pending | Jul 28, 2022 |
| 17792639 | MOLECULE DESIGN | SANFORD, DIANA PATRICIA | 1687 | §101§103 | Final Rejection | 23d overdue | Pending | Jul 13, 2022 |
| 17577942 | RECOMBINASE COMPOSITIONS AND METHODS OF USE | MCLEOD, AFRICA MHAIRIE | 1635 | §112 | Final Rejection | 21d | Pending | Jan 18, 2022 |
| 17433639 | CIRCULAR POLYRIBONUCLEOTIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ZAHORIK, AMANDA MARY | 1636 | §102§103 | Final Rejection | 8d overdue | Pending | Aug 25, 2021 |
| 17428356 | MACHINE LEARNING GUIDED POLYPEPTIDE ANALYSIS | PRESSLY, KURT NICHOLAS | 2125 | §101 | Non-Final OA | — | Pending | Aug 04, 2021 |
| 18846524 | NOVEL ANELLOVIRIDAE FAMILY VECTOR COMPOSITIONS AND METHODS | CANDELARIA, JULIANA IRENE | 1634 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 12, 2024 |
| 18559921 | ANELLOVECTORS AND METHODS OF USE | MATALKAH, FATIMAH KHALAF | 1638 | §103DP | Non-Final OA | — | Pending | Nov 09, 2023 |
| 18257483 | COMPOSITIONS AND METHODS FOR MODULATING MYC EXPRESSION | COFFA, SERGIO | 1658 | §112DP | Final Rejection | — | Pending | Jun 14, 2023 |
| 18201882 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | LEE, WILLIAM Y | 1623 | §112 | Non-Final OA | — | Pending | May 25, 2023 |
| 18154618 | COMPOSITIONS FOR FACILITATING MEMBRANE FUSION AND USES THEREOF | LIU, TRACY | 1614 | §103 | Final Rejection | 5d | Pending | Jan 13, 2023 |
| 17413123 | ANELLOSOMES FOR DELIVERING INTRACELLULAR THERAPEUTIC MODALITIES | TRAN, CHRISTINA L | 1637 | §103Other | Non-Final OA | 67d overdue | Pending | Jun 11, 2021 |
| 17413297 | ANELLOSOMES FOR DELIVERING PROTEIN REPLACEMENT THERAPEUTIC MODALITIES | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103Other | Final Rejection | 45d overdue | Pending | Jun 11, 2021 |
| 17218025 | TARGETED LIPID PARTICLES AND COMPOSITIONS AND USES THEREOF | TIWARI, VYOMA SHUBHAM | 1634 | §103 | Non-Final OA | — | Pending | Mar 30, 2021 |
| 16970216 | COMPOSITIONS AND METHODS FOR MEMBRANE PROTEIN DELIVERY | RIGA, MICHAEL ANGELO | 1634 | §103§112 | Final Rejection | 28d overdue | Pending | Aug 14, 2020 |
| 18283262 | PRODUCTION OF CIRCULAR POLYRIBONUCLEOTIDES IN A PROKARYOTIC SYSTEM | BRETZ, COREY LANE | 1635 | §103DP | Non-Final OA | — | Pending | Sep 21, 2023 |
| 18283257 | COMPOSITIONS AND METHODS FOR PRODUCING CIRCULAR POLYRIBONUCLEOTIDES | ZARA, JANE J | 1637 | §103§112Other | Non-Final OA | — | Pending | Sep 21, 2023 |
| 18283242 | PRODUCTION OF CIRCULAR POLYRIBONUCLEOTIDES IN A EUKARYOTIC SYSTEM | SULLIVAN, STEPHANIE LAUREN | 1635 | §103DP | Non-Final OA | — | Pending | Sep 21, 2023 |
| 18362410 | IMMUNOMODULATORY PROTEINS AND RELATED METHODS | YU, MISOOK | 1641 | §103DP | Non-Final OA | 21d | Pending | Jul 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFlagship Pioneering Inc. has 50 pending office actions as of October 2026, spread across 25 art units and 45 examiners.
Nancy J Leith has the most, with 2 of Flagship Pioneering Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
